Skip to main content

Table 2 Transition matrix for the treatment pathway metformin+dipeptidyl peptidase-4 inhibitor

From: Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes

   To t + 1
   Metformin monotherapy Metformin +DPP-4i Metformin +DPP-4i + Basal insulin Death
From t Metformin monotherapy # 0.046 0 60–70 years; 0.021
71–80 years; 0.051
81–85 years; 0.107
  Metformin +DPP-4i 0 # 0.013 60–70 years; 0.021
71–80 years; 0.051
81–85 years; 0.107
  Metformin +DPP-4i + Basal insulin 0 0 # 60–70 years; 0.021
71–80 years; 0.051
81–85 years; 0.107
  Death 0 0 0 1
  1. Acronyms: DPP-4i-dipeptidyl peptidase-4 inhibitors